De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Nyxoah Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Olivier Taelman

Algemeen directeur

€807.1k

Totale compensatie

Percentage CEO-salaris	54.1%
Dienstverband CEO	4.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Recent updates

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Dec 21

Analyse CEO-vergoeding

Hoe is Olivier Taelman's beloning veranderd ten opzichte van Nyxoah's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€44m
Mar 31 2024	n/a	n/a	-€43m
Dec 31 2023	€807k	€436k	-€43m
Sep 30 2023	n/a	n/a	-€46m
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€36m
Dec 31 2022	€631k	€436k	-€31m
Sep 30 2022	n/a	n/a	-€24m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€29m
Dec 31 2021	€731k	€413k	-€28m
Sep 30 2021	n/a	n/a	-€25m
Jun 30 2021	n/a	n/a	-€21m
Mar 31 2021	n/a	n/a	-€16m
Dec 31 2020	€336k	€263k	-€12m

Compensatie versus markt: De totale vergoeding ($USD 893.40K ) Olivier } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Belgian markt ($USD 759.56K ).

Compensatie versus inkomsten: De vergoeding van Olivier is gestegen terwijl het bedrijf verliesgevend is.

CEO

Olivier Taelman (53 yo)

4.9yrs

Tenure

€807,096

Compensatie

Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	8.21% € 23.7m
Olivier Taelman	CEO & Executive Director	4.9yrs	€807.10k	geen gegevens
Loic Moreau	Chief Financial Officer	2.8yrs	€468.69k	0.038% € 110.8k
Bruno Onkelinx	Chief Technology Officer	3.6yrs	geen gegevens	geen gegevens
Mikaela Kirkwood	Corporate Communication & Investor Relations Manager	no data	geen gegevens	geen gegevens
An Moonen	General Counsel	3.8yrs	geen gegevens	geen gegevens
Inge Vanwittenbergh	Global Human Resource Director	1.8yrs	geen gegevens	geen gegevens
David DeMartino	Chief Strategy Officer	1.8yrs	geen gegevens	geen gegevens
Remi Renard	Chief of Staff	less than a year	geen gegevens	geen gegevens
Jeyakumar Subbaroyan	Chief Clinical Officer	less than a year	geen gegevens	geen gegevens
Francis Kim	Chief Regulatory & Quality Officer	less than a year	geen gegevens	geen gegevens
Maurits Boon	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NYXH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	8.21% € 23.7m
Olivier Taelman	CEO & Executive Director	4.1yrs	€807.10k	geen gegevens
Kevin Rakin	Independent Non-Executive Director	8.3yrs	€68.59k	0.36% € 1.0m
Jurgen Hambrecht	Independent Non-Executive Director	4.8yrs	€58.50k	3.91% € 11.3m
Daniel Wildman	Independent Non-Executive Director	1.8yrs	€71.28k	geen gegevens
Virginia Kirby	Independent Non-Executive Director	2.3yrs	€59.22k	0.016% € 46.6k
Rita Johnson-Mills	Independent Non-Executive Director	3.2yrs	€63.62k	0.016% € 46.6k
Pierre Gianello	Non-Executive Director	6.8yrs	€175.63k	0.034% € 96.9k

4.4yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NYXH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Nyxoah Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Recent updates

Nyxoah S.A. Presents Dream U.S. Study Data At Isss 2024, Showing Significant Ahi Reduction and Quality-Of-Life Improvements

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

Price target decreased by 7.6% to €13.40

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

New minor risk - Shareholder dilution

Nyxoah S.A. has filed a Follow-on Equity Offering.

First quarter 2024 earnings released: €0.41 loss per share (vs €0.46 loss in 1Q 2023)

Full year 2023 earnings released: €1.51 loss per share (vs €1.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

New major risk - Share price stability

Price target decreased by 13% to €9.65

Nyxoah SA Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio(R)

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Revenue and earnings growth

New major risk - Financial position

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings released: €0.45 loss per share (vs €0.19 loss in 2Q 2022)

First quarter 2023 earnings released: €0.46 loss per share (vs €0.26 loss in 1Q 2022)

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Full year 2022 earnings released: €1.21 loss per share (vs €1.16 loss in FY 2021)

Nyxoah S.A. to Report Q3, 2023 Results on Nov 08, 2023

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Third quarter 2022 earnings released: €0.24 loss per share (vs €0.29 loss in 3Q 2021)

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Second quarter 2022 earnings released: €0.19 loss per share (vs €0.31 loss in 2Q 2021)

Nyxoah S.A. Announces CE Mark Approval for Genio® 2.1

Nyxoah SA Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

Nyxoah S.A. Announces U.S. Food and Drug Administration Approved the Use of Nyxoah's Next Generation Genio 2.1 System

Nyxoah S.A. Announces Board Changes

Nyxoah S.A. to Report First Half, 2022 Results on Aug 09, 2022

Nyxoah S.A. to Report Fiscal Year 2021 Results on Mar 24, 2022

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Deleted from Other OTC

Nyxoah SA's BETTER SLEEP Trial Reaches its Primary Endpoints

New 90-day high: €19.90

Nyxoah Receives FDA Approval for Full-Body 1.5T and 3T MRI Compatibility for the Genio System to Treat Obstructive Sleep Apnea

New 90-day high: €18.50

Nyxoah S.A. Announces First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio System for the Treatment of Obstructive Sleep Apnea

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Nyxoah S.A. Announces First Patient Implanted in the Dream US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea

Nyxoah S.A. has filed an IPO in the amount of €75.67805 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd